Esperavir® – the best launch of 2021 in the budget sales segment according to IQVIA
Esperavir® manufactured by Promomed Group was ranked #1 in the category «The best launch of prescription drug in the segment of sales for public sector in 2021» at the IQVIA RX and Consumer Health Awards.
Esperavir®developed by Promomed Group became a winner of the award IQVIA RX And Consumer Health, which takes place as part of the annual event IQVIA Client Day, in the category «The best launch of prescription drug in the segment of sales for public sector in 2021». The winners in each nomination were determined according to the information from databases on subsidized drug supply in the Russian Federation. One of the mandatory conditions for the selection of nominees was the absence of the drug on the market until 2021.
«Winning the IQVIA RX And Consumer Health award is primarily a recognition of the product quality and of relevance. Esperavir is unique not only for its mechanism of action in terms of therapy, but also for becoming the first drug in Russia to treat coronavirus using a molecule recognized by the medical community at the international level. This award is an excellent motivation for our team not to stop where we are,» said Maxim Smagin, General Director of Promomed.
The first drug for COVID-19, Areplivir® (favipiravir), was offered by the company to patients and doctors back in mid-2020. Almost immediately, the drug was included in the guidelines on treating COVID-19 infections approved by the Russian Ministry of Health; the Russian Government included it in the list of vital and essential drugs since 21.10.2020. Promomed continues to expand its anti-COVID drug portfolio; the company believes that it is extremely important for doctors to have a wide range of etiotropic therapy options. To date, the company produces about 30 medicines for the treatment of coronavirus infection and its complications.
